From Channel Dependency to Diversified Drivers: It is the Right Time for Futures Companies to Break Through with Differentiation

老虎证券2026/04/10 21:22

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to incomplete statistics from China Securities Journal, 33 futures companies have released their annual “report cards” so far. A review of the data shows that leading firms delivered impressive performances: the net profit of the top 9 futures companies totaled 5.693 billion yuan, accounting for more than half of the total net profit of all 150 futures companies across the industry, highlighting an increasingly prominent "Matthew effect" in the sector.Industry insiders believe that in 2025, performance differentiation among futures firms will continue to intensify. The core reasons are the widening gaps in capital strength, shareholder resources, and comprehensive service capabilities among institutions. As industry competition becomes increasingly fierce and growth in traditional brokerage business stalls, futures companies are gradually moving away from reliance on channel business and shifting toward diversified business-driven transformation. Looking ahead, the industry will enter a stage of high-quality competition, and differentiated development will become the key path for all types of futures companies to break through.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11